SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes
Phase of Trial: Phase II
Latest Information Update: 18 May 2019
Price : $35 *
At a glance
- Drugs Regorafenib (Primary)
- Indications Ewing's sarcoma; Liposarcoma; Osteosarcoma; Rhabdomyosarcoma
- Focus Therapeutic Use
- 23 Apr 2019 Results in the cohort for patients with advanced or metastatic osteosarcoma, published in the Journal of Clinical Oncology
- 05 Jun 2018 Results of a cohort of patients with treatment-refractory liposarcoma (n=47) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 26 Feb 2018 Cohort D (Rhabdomyosarcoma) has been added and patient number also increased.